Stock Scorecard
Stock Summary for Celldex Therapeutics Inc (CLDX) - $41.48 as of 4/18/2024 6:14:09 PM EST
Total Score
7 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CLDX
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CLDX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CLDX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 |
Bonus Criteria for CLDX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for CLDX
Financial Details for CLDX
Company Overview |
|
|---|---|
| Ticker | CLDX |
| Company Name | Celldex Therapeutics Inc |
| Country | USA |
| Description | Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey. |
| Sector Name | LIFE SCIENCES |
| Industry Name | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Most Recent Quarter | 12/31/2023 |
| Next Earnings Date | 5/2/2024 |
Stock Price History |
|
| Last Day Price | 41.48 |
| Last Day Price Updated | 4/18/2024 6:14:09 PM EST |
| Last Day Volume | 954,933 |
| Average Daily Volume | 800,706 |
| 52-Week High | 53.18 |
| 52-Week Low | 22.11 |
| Last Price to 52 Week Low | 87.61% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 223.35 |
| Sector PE | 61.34 |
| 5-Year Average PE | -13.11 |
| Free Cash Flow Ratio | 6.43 |
| Industry Free Cash Flow Ratio | 36.30 |
| Sector Free Cash Flow Ratio | 30.16 |
| Current Ratio Most Recent Quarter | 13.87 |
| Total Cash Per Share | 6.45 |
| Book Value Per Share Most Recent Quarter | 7.68 |
| Price to Book Ratio | 6.01 |
| Industry Price to Book Ratio | 11.27 |
| Sector Price to Book Ratio | 22.08 |
| Price to Sales Ratio Twelve Trailing Months | 374.64 |
| Industry Price to Sales Ratio Twelve Trailing Months | 5.80 |
| Sector Price to Sales Ratio Twelve Trailing Months | 5.19 |
Share Statistics |
|
| Total Shares Outstanding | 65,699,000 |
| Market Capitalization | 2,725,194,520 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Dividend Aristocrat? | False |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 2.16% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -32.29% |
| Reported EPS 12 Trailing Months | -2.92 |
| Reported EPS Past Year | 0.00 |
| Reported EPS Prior Year | -2.91 |
| Net Income Twelve Trailing Months | -126,288,000 |
| Net Income Past Year | -126,288,000 |
| Net Income Prior Year | -95,463,000 |
| Quarterly Revenue Growth YOY | 156.10% |
| 5-Year Revenue Growth | -6.31% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 423,598,000 |
| Total Cash Past Year | 423,598,000 |
| Total Cash Prior Year | 304,952,000 |
| Net Cash Position Most Recent Quarter | 423,598,000 |
| Net Cash Position Past Year | 423,598,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 429,171,000 |
| Total Stockholder Equity Prior Year | 326,204,000 |
| Total Stockholder Equity Most Recent Quarter | 429,171,000 |
Options |
|
| Put/Call Ratio | 0.18 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.90 |
| MACD Signal | -0.74 |
| 20-Day Bollinger Lower Band | 31.63 |
| 20-Day Bollinger Middle Band | 39.96 |
| 20-Day Bollinger Upper Band | 48.29 |
| Beta | 1.56 |
| RSI | 41.88 |
| 50-Day SMA | 34.45 |
| 200-Day SMA | 31.72 |
System |
|
| Modified | 4/17/2024 9:11:01 PM EST |